Leadership Team

Axovant has assembled a team with decades of combined experience in developing, obtaining approval, and commercializing drugs for central nervous system disorders.

 David T. Hung, MD*

David T. Hung, MD*

Chief Executive Officer

Dr. Hung has served as Chief Executive Officer of Axovant Sciences, Inc. and a member of the board since April 2017. Previously, he was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its President and Chief Executive Officer and a member of its board of directors until its acquisition by Pfizer Inc. Before that, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer and then as President and Chief Executive Officer. He has also served as a consultant to Cytyc Corporation to assist with transitional matters related to its acquisition of ProDuct Health, Inc. and has served as a member of the board of directors of Opexa Therapeutics, Inc., a biopharmaceutical company. Dr. Hung received an MD from the University of California, San Francisco, School of Medicine, and an AB in biology from Harvard College.

 Marion McCourt*

Marion McCourt*

President & Chief Operating Officer

Ms. McCourt has served as president and chief operating officer of Axovant Sciences, Inc. since April 2017. She has more than two decades of wide-ranging experience at some of the world’s most innovative biopharmaceutical companies. She has extensive experience leading commercial functions including medical affairs, business development, finance, human resources, legal, operations, payer-government, and sales and marketing. Before joining Axovant, she was Chief Operating Officer of Medivation, Inc. until its acquisition by Pfizer Inc. Earlier in her career, she held multiple roles at Amgen including Vice President in US Commercial Operations and Vice President and General Manager at Amgen, where she was responsible for the bone health and primary care business unit. She served in a number of roles of increasing responsibility during a 12-year career at AstraZeneca including ultimately as Chief Operating Officer for AstraZeneca US. She received a BS in biology from Lafayette College.

Mark Altmeyer**

Mark Altmeyer**

President of Axovant Sciences GmbH & Chief Commercial Officer

Mr. Altmeyer is the Chief Commercial Officer of Axovant Sciences GmbH and joined the company in March 2015. He has three decades of experience leading successful drug commercialization efforts as a pharmaceutical executive, with a particular focus on therapies for central nervous system disorders. Previously, he served as Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc., where he led 1,700 employees and grew total revenues from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number one selling drug in the United States in 2013. Earlier in his career, Mr. Altmeyer held a number of executive leadership roles at Bristol-Myers Squibb including senior vice president, Global Commercialization, and senior vice president, Neuroscience Business Unit. He received an MBA from Harvard Business School and a BA from Middlebury College.

Lawrence T. Friedhoff, MD, PhD, FACP*

Lawrence T. Friedhoff, MD, PhD, FACP*

Chief Development Officer

Dr. Friedhoff has served as Chief Development Officer of Axovant Sciences, Inc. since May 2015. He has a 30-year record of identifying promising drug candidates and managing all phases of their development, always with an eye toward fulfilling drug approval requirements. He has managed post-FDA-approval activities including marketing-related, safety surveillance and post-approval studies. He is currently Chief of Research and Development at Roivant Sciences, Inc. Previously, he held positions at Eisai, Squibb and Andrx Corporation. At Eisai, he led the drug development team for Aricept® (donepezil), the top-selling drug for Alzheimer’s disease in history, and the new drug approval team for AcipHex® (rabeprazole) for the treatment of heartburn. He is the author of the book New Drugs and author or co-author of many peer-reviewed publications in major scientific journals. He received an MD from New York University School of Medicine and a PhD in chemistry from Columbia University. He is a fellow of the American College of Physicians.

Ilise Lombardo, MD

Ilise Lombardo, MD

Senior Vice President, Clinical Research

Dr. Lombardo has served as Senior Vice President, clinical research, at Axovant Sciences. Inc. since April 2015. She has 15 years of experience in the pharmaceutical industry leading clinical development and medical affairs programs across multiple therapeutic areas including neurological and psychiatric disorders. She has successfully managed clinical development, regulatory authority approval and post-marketing activities. She is a trained psychiatrist and previously worked in academic research and clinical practice. Previously, she was Vice President, Clinical Development and Medical Affairs, at FORUM Pharmaceuticals. Earlier in her career, she led multi-therapeutic groups and development teams at Pfizer Inc. Prior to entering the pharmaceutical industry, she was an Assistant Professor of Clinical Research at Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute. She received an MD from Yale University, an M.Phil. from the University of Cambridge, and an AB from Brown University.

Gregory M. Weinhoff, MD*

Gregory M. Weinhoff, MD*

Chief Financial Officer

Dr. Weinhoff has served as Chief Financial Officer of Axovant Sciences, Inc. since August 2015. He has more than 20 years of experience in healthcare finance and operations including as a venture capital investor, operating executive and board member with Audit Committee experience. Previously, he was a partner at CHL Medical Partners, where he focused on investments in start-up and early-stage companies across therapeutics, diagnostics, medical devices and healthcare services. He was the founding Chief Executive Officer of Amicus Therapeutics and was subsequently a member of the Audit Committee of the company’s board of directors. Earlier in his career, he was founding President of VaxInnate and President of Resolvyx. He also held positions in the healthcare groups at J.H. Whitney & Co. and Morgan Stanley & Co. He received an MD from Harvard Medical School, an MBA from Harvard Business School (Baker Scholar), and an AB in economics (magna cum laude) from Harvard College.

Stephen F. Mohr*

Stephen F. Mohr*

General Counsel

Mr. Mohr has served as General Counsel of Axovant Sciences, Inc. since June 2017. He served in a number of senior roles during a 12-year career at AstraZeneca, including US General Counsel and Deputy General Counsel, North America and Global Compliance Officer. Prior to that, he held roles of increasing responsibility during a 14-year career at Bristol-Myers Squibb, including Vice President and Senior Counsel, US Medicines. He has more than 25 years of experience in legal and compliance matters affecting the pharmaceutical industry. Earlier in his career, he specialized in litigation matters at Weiss Dawid Fross Zelnick & Lehrman, PC (now Fross Zelnick Lehrman & Zissu) and Rivkin Leff Sherman & Radler (now Rivkin Radler LLP). Mr. Mohr received a JD from the University of Virginia School of Law and a BA (magna cum laude) from Yale University.

Eric Floyd, PhD

Eric Floyd, PhD

Senior Vice President, Regulatory Affairs

Dr. Floyd has served as senior vice president, regulatory affairs, for Axovant Sciences, Inc. since June 2017. He has nearly 20 years of regulatory experience within the pharmaceutical industry. Most recently, he was president of compliance services and chief scientific officer at Dohmen Life Science Services, Inc. He was Senior Vice President, US Regulatory Affairs and Clinical Quality Compliance at Lundbeck Inc., Global Vice President of Regulatory Affairs at Hospira, Vice President of Worldwide Regulatory Affairs and Quality Assurance at Cephalon and VP and Global Head of Respiratory, Dermatology, and Tropical Medicines Drug Regulatory Affairs at Novartis and held senior leadership roles at Bristol Myers Squibb, Aventis and Merck Research Laboratories. Dr. Floyd received a Ph.D. from Meharry Medical College, Nashville, an MBA from St. Joseph’s University, Philadelphia, an MS from Tennessee State University, and a BS from the University of Illinois.

Thomas Templeman, PhD

Thomas Templeman, PhD

Senior Vice President, Pharmaceutical Operations and Quality Assurance

Dr. Templeman has served as Senior Vice President, Pharmaceutical Operations and Quality Assurance, for Axovant Sciences, Inc. since June 2017. He has more than 25 years of experience across various aspects of pharmaceutical operations. He most recently served as Chief Operations Officer at Graybug Vision, and was at Medivation prior to that. He previously held positions of increasing responsibility at Hospira, Inc., Liquidia Technologies, and the Johnson & Johnson companies Centocor Biologics and Ortho Clinical Diagnostics. Dr. Templeman received a PhD from Dartmouth College and a BS from the University of Santa Clara.

Mark Wadley

Mark Wadley

Senior Vice President, US Business

Mr. Wadley has served as Senior Vice President, US Business, for Axovant Sciences, Inc. since May 2017. He has 24 years of commercial leadership experience across sales, marketing, payer access and commercial operations. Mr. Wadley most recently served as Senior Vice President of Sales at Guardant Health and previously was Vice President Oncology Sales, Organized Customers, and Payer at Medivation. He has also held various roles of increasing responsibility at Amgen, Wyeth BioPharma and Genetics Institute. Mr. Wadley holds a BS from Arizona State University.

Samina Bari

Samina Bari

Vice President, Corporate Communications

Ms. Bari has served as Vice President, Corporate Communications, for Axovant Sciences, Inc. since May 2017. She has more than 25 years of US and global communications experience in the healthcare and pharmaceutical industries. Most recently, she was Vice President of Corporate Communications at Medivation, and was Senior Vice President of Corporate Communications at Pharmacyclics prior to that. She has also held positions of increasing responsibility at Ikaria, Johnson & Johnson and Pfizer, in addition to having held senior-level positions at several of the world’s leading global communications firms. She began her career at a New York teaching hospital. Ms. Bari holds an MA and BA from New York University.

Shankar Ramaswamy, MD

Shankar Ramaswamy, MD

Vice President, Global Medical Affairs

Dr. Ramaswamy is the vice president of global medical affairs for Axovant Sciences, Inc. and joined the company in March 2015. Dr. Ramaswamy was one of the earliest employees of Axovant and has served the company in multiple roles, including most recently as Vice President, Medical and Scientific Communications. He was also involved in the scientific evaluation of new assets for Axovant. Dr. Ramaswamy holds an AB in Economics from Harvard University and a MD from Brown University.

** Employee and officer of Axovant Sciences, Inc.
** Employee and officer of Axovant Sciences GmbH